On 12 February 2015, orphan designation (EU/3/15/1445) was granted by the European Commission to Bristol-Myers Squibb Pharma EEIG, United Kingdom, for ulocuplumab for the treatment of acute myeloid leukaemia.
The sponsor’s address was updated in July 2019.
Please note that this product was withdrawn from the Union Register of orphan medicinal products in December 2019 on request of the Sponsor.
|Disease / condition||
Treatment of acute myeloid leukaemia
|Date of first decision||
|EU designation number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
- European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
- Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;